Process / pipelineBioinformaticsBioinformatics / omicsPipeline

eQTL Analysis — Expression Quantitative Trait Loci Analysis

Also known as: eQTL mapping, expression QTL analysis, transcriptomic QTL analysis, eQTL study

OriginatorRitsert C. Jansen & Jan-Peter NapYear2001 (term coined); widely adopted after 2005Sources2Related methods21

eQTL analysis identifies genomic loci (variants, typically SNPs) whose genotype statistically associates with variation in the expression level of one or more genes. By jointly profiling DNA-level variation and RNA-level expression in the same individuals, eQTL studies decode the regulatory grammar of the genome — revealing which variants control how much a gene is transcribed, in which tissues, and under what conditions.

Key highlights

  • Directly links DNA-level variation to gene expression, providing mechanistic insight beyond standard GWAS.
  • Enables prioritization of causal genes at non-coding GWAS loci through colocalisation analysis.
  • Scalable to whole transcriptome and whole genome simultaneously with established software pipelines (Matrix eQTL, FastQTL, TensorQTL).
  • Applicable across tissues, cell types, developmental stages, and disease contexts to reveal regulatory context-specificity.
  • Well-powered cis-eQTL analyses (n ≥ 150–200) reliably detect moderate-to-large regulatory effects.

Intuition

This section is available to Pro members. Upgrade to Pro

How it works

This section is available to Pro members. Upgrade to Pro

When to use it

Use eQTL analysis when you have paired genotype and gene expression data from the same individuals (typically n ≥ 100, ideally several hundred or more) and want to map genetic regulatory effects on transcription. It is the appropriate method for prioritising causal genes at GWAS loci, understanding tissue-specific gene regulation, and building multi-tissue regulatory atlases. Do not use eQTL analysis if genotype and expression data are from different individuals, if sample sizes are below ~50 (power is too low to detect all but the largest effects), or if the biological question is about differential expression between conditions rather than genetic control of expression. Single-cell eQTL mapping requires specialized methods that account for the additional cellular-level heterogeneity and is a distinct analytical pipeline.

Strengths & limitations

Strengths
  • Directly links DNA-level variation to gene expression, providing mechanistic insight beyond standard GWAS.
  • Enables prioritization of causal genes at non-coding GWAS loci through colocalisation analysis.
  • Scalable to whole transcriptome and whole genome simultaneously with established software pipelines (Matrix eQTL, FastQTL, TensorQTL).
  • Applicable across tissues, cell types, developmental stages, and disease contexts to reveal regulatory context-specificity.
  • Well-powered cis-eQTL analyses (n ≥ 150–200) reliably detect moderate-to-large regulatory effects.
Limitations
  • Requires large, well-matched cohorts — power to detect eQTLs, especially trans, drops sharply below n ≈ 100.
  • Trans-eQTL mapping is severely underpowered and inflated by technical artefacts unless very large samples and careful QC are used.
  • Identifies statistical associations, not causal regulatory mechanisms — fine-mapping and functional experiments are needed to confirm causality.
  • Results are tissue- and cell-type-specific; eQTLs detected in bulk tissue may not reflect the relevant cell population.
  • Cannot resolve dynamic regulation over time from a single time-point cross-sectional design.

Common pitfalls

This section is available to Pro members. Upgrade to Pro

Applications

This section is available to Pro members. Upgrade to Pro

Frequently asked

What is the difference between a cis-eQTL and a trans-eQTL?

A cis-eQTL is a variant whose effect on gene expression is detected within a defined genomic window around the gene it regulates (commonly ±1 Mb). A trans-eQTL lies outside that window and acts at a distance — often through transcription factors or other intermediaries. Cis-eQTLs are more numerous, easier to detect, and less prone to false positives; trans-eQTLs require very large samples and strict multiple-testing thresholds because the search space is vastly larger.

How large a sample do I need for a well-powered eQTL study?

For cis-eQTL detection of moderate-effect variants, n ≈ 100–200 is the minimum often cited, but power increases substantially up to n ≈ 500 and beyond. Robust trans-eQTL mapping typically requires n > 1000. The required sample size also depends on effect size, allele frequency, expression noise, and the stringency of the multiple-testing correction. Power calculators such as those provided in the FastQTL documentation can inform study design.

How do I know if an eQTL is also responsible for a GWAS signal?

Colocalisation analysis — for example, using the coloc R package or its extensions (HyPrColoc for multi-trait) — formally tests whether an eQTL and a GWAS signal at the same locus are driven by the same causal variant or merely sit in the same region by coincidence. A posterior probability of colocalisation (PP4) above ~0.8 is conventionally taken as evidence that the two signals share a causal variant.

Can I run eQTL analysis on single-cell RNA-seq data?

Yes, but single-cell eQTL mapping (sc-eQTL) requires additional methodological considerations: aggregating counts to pseudo-bulk profiles per donor per cell type before testing, accounting for variable numbers of cells per donor, and correcting for cell-type-proportion differences. Tools such as tensorQTL with pseudo-bulk input or dedicated sc-eQTL frameworks (e.g., scPower, FactorQTL) are recommended over naive application of bulk-tissue pipelines.

What software is commonly used for eQTL analysis?

Matrix eQTL (R package) is widely used for its speed and flexibility. FastQTL and TensorQTL (GPU-accelerated) are standard choices for large cohorts. PEER or similar methods handle latent factor covariate estimation. For colocalisation, the coloc R package is the community standard. The GTEx analysis pipeline is publicly documented and serves as a reproducible reference implementation.

Sources

  1. 1.
    Jansen, R. C., & Nap, J.-P. (2001). Genetical genomics: the added value from segregation. Trends in Genetics, 17(7), 388–391.
  2. 2.
    GTEx Consortium (2020). The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science, 369(6509), 1318–1330.

You have read it. What now?

Cite this page

ScholarGate. (2026, June 3). eQTL Analysis. ScholarGate. https://scholargate.app/bioinformatics/eqtl-analysis